Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in Human Phase I, Non-randomised, Open-label, Multi-center Dose Escalation Trial of BI 836880 Administered by Repeated Intravenous Infusions in Patients With Solid Tumors

Next Previous
Trial Profile

A First-in Human Phase I, Non-randomised, Open-label, Multi-center Dose Escalation Trial of BI 836880 Administered by Repeated Intravenous Infusions in Patients With Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Feb 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BI 836880 (Primary)
  • Indications Breast cancer; Nasopharyngeal cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 03 Feb 2021 Status changed from active, no longer recruiting to completed.
  • 04 Oct 2020 Planned End Date changed from 31 Oct 2020 to 31 Dec 2020.
  • 29 Jun 2020 Planned End Date changed from 30 May 2020 to 31 Oct 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top